APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dermatomycoses Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Dermatomycoses Drug Market Outlook and Growth Opportunities 2026

26 December 2025196 pages

Choose your research edition.

Industry ResearchDermatomycoses Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Dermatomycoses Drug Industry Growth and Trends Forecast to 2032107 pages · $3,450 USDMarket StructureGlobal Dermatomycoses Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dermatomycoses Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Dermatomycoses Drug Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Dermatomycoses Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Dermatomycoses Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dermatomycoses Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dermatomycoses Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Dermatomycoses Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Dermatomycoses Drug market include Vyome Biosciences Pvt Ltd, Viamet Pharmaceuticals Inc, TGV-Laboratories, Sol-Gel Technologies Ltd, Novan Inc, Helix BioMedix Inc, Dermala Inc, Daewoong Pharmaceutical Co Ltd and Blueberry Therapeutics Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dermatomycoses Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dermatomycoses Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dermatomycoses Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dermatomycoses Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Dermatomycoses Drug Segment by Company

Vyome Biosciences Pvt Ltd

Viamet Pharmaceuticals Inc

TGV-Laboratories

Sol-Gel Technologies Ltd

Novan Inc

Helix BioMedix Inc

Dermala Inc

Daewoong Pharmaceutical Co Ltd

Blueberry Therapeutics Ltd

Biolab Farmaceutica Ltda

Anacor Pharmaceuticals Inc

Dermatomycoses Drug Segment by Type

BB-2603

Dapaconazole

Clotrimazole

Others

Dermatomycoses Drug Segment by Application

Hospital

Clinic

Others

Dermatomycoses Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Dermatomycoses Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Dermatomycoses Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Dermatomycoses Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Dermatomycoses Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dermatomycoses Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dermatomycoses Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dermatomycoses Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dermatomycoses Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Dermatomycoses Drug industry.

Chapter 3: Detailed analysis of Dermatomycoses Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Dermatomycoses Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Dermatomycoses Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Dermatomycoses Drug Industry Trends Table 2. Dermatomycoses Drug Industry Drivers Table 3. Dermatomycoses Drug Industry Opportunities and Challenges Table 4. Dermatomycoses Drug Industry Restraints Table 5. Global Dermatomycoses Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Dermatomycoses Drug Revenue Share by Company (2021-2026) Table 7. Global Dermatomycoses Drug Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Dermatomycoses Drug Sales Volume Share by Company (2021-2026) Table 9. Global Dermatomycoses Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Dermatomycoses Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Dermatomycoses Drug Key Company Manufacturing Base & Headquarters Table 12. Global Dermatomycoses Drug Company, Product Type & Application Table 13. Global Dermatomycoses Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Dermatomycoses Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of BB-2603 Table 18. Significant Companies of Dapaconazole Table 19. Significant Companies of Clotrimazole Table 20. Significant Companies of Others Table 21. Global Dermatomycoses Drug Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Dermatomycoses Drug Sales Volume by Type (2021-2026) & (W Units) Table 23. Global Dermatomycoses Drug Sales Volume by Type (2027-2032) & (W Units) Table 24. Global Dermatomycoses Drug Sales Volume Share by Type (2021-2026) Table 25. Global Dermatomycoses Drug Sales Volume Share by Type (2027-2032) Table 26. Global Dermatomycoses Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Dermatomycoses Drug Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Dermatomycoses Drug Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Dermatomycoses Drug Sales Value Share by Type (2021-2026) Table 30. Global Dermatomycoses Drug Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Hospital Table 32. Significant Companies of Clinic Table 33. Significant Companies of Others Table 34. Global Dermatomycoses Drug Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global Dermatomycoses Drug Sales Volume by Application (2021-2026) & (W Units) Table 36. Global Dermatomycoses Drug Sales Volume by Application (2027-2032) & (W Units) Table 37. Global Dermatomycoses Drug Sales Volume Share by Application (2021-2026) Table 38. Global Dermatomycoses Drug Sales Volume Share by Application (2027-2032) Table 39. Global Dermatomycoses Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global Dermatomycoses Drug Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global Dermatomycoses Drug Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global Dermatomycoses Drug Sales Value Share by Application (2021-2026) Table 43. Global Dermatomycoses Drug Sales Value Share by Application (2027-2032) Table 44. Global Dermatomycoses Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global Dermatomycoses Drug Sales by Region (2021-2026) & (W Units) Table 46. Global Dermatomycoses Drug Sales Market Share by Region (2021-2026) Table 47. Global Dermatomycoses Drug Sales by Region (2027-2032) & (W Units) Table 48. Global Dermatomycoses Drug Sales Market Share by Region (2027-2032) Table 49. Global Dermatomycoses Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Dermatomycoses Drug Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global Dermatomycoses Drug Sales Value Share by Region (2021-2026) Table 52. Global Dermatomycoses Drug Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global Dermatomycoses Drug Sales Value Share by Region (2027-2032) Table 54. Global Dermatomycoses Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global Dermatomycoses Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global Dermatomycoses Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Global Dermatomycoses Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Dermatomycoses Drug Sales by Country (2021-2026) & (W Units) Table 59. Global Dermatomycoses Drug Sales Market Share by Country (2021-2026) Table 60. Global Dermatomycoses Drug Sales by Country (2027-2032) & (W Units) Table 61. Global Dermatomycoses Drug Sales Market Share by Country (2027-2032) Table 62. Global Dermatomycoses Drug Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global Dermatomycoses Drug Sales Value Market Share by Country (2021-2026) Table 64. Global Dermatomycoses Drug Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global Dermatomycoses Drug Sales Value Market Share by Country (2027-2032) Table 66. Vyome Biosciences Pvt Ltd Company Information Table 67. Vyome Biosciences Pvt Ltd Business Overview Table 68. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Portfolio Table 70. Vyome Biosciences Pvt Ltd Recent Development Table 71. Viamet Pharmaceuticals Inc Company Information Table 72. Viamet Pharmaceuticals Inc Business Overview Table 73. Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio Table 75. Viamet Pharmaceuticals Inc Recent Development Table 76. TGV-Laboratories Company Information Table 77. TGV-Laboratories Business Overview Table 78. TGV-Laboratories Dermatomycoses Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. TGV-Laboratories Dermatomycoses Drug Product Portfolio Table 80. TGV-Laboratories Recent Development Table 81. Sol-Gel Technologies Ltd Company Information Table 82. Sol-Gel Technologies Ltd Business Overview Table 83. Sol-Gel Technologies Ltd Dermatomycoses Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Sol-Gel Technologies Ltd Dermatomycoses Drug Product Portfolio Table 85. Sol-Gel Technologies Ltd Recent Development Table 86. Novan Inc Company Information Table 87. Novan Inc Business Overview Table 88. Novan Inc Dermatomycoses Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Novan Inc Dermatomycoses Drug Product Portfolio Table 90. Novan Inc Recent Development Table 91. Helix BioMedix Inc Company Information Table 92. Helix BioMedix Inc Business Overview Table 93. Helix BioMedix Inc Dermatomycoses Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Helix BioMedix Inc Dermatomycoses Drug Product Portfolio Table 95. Helix BioMedix Inc Recent Development Table 96. Dermala Inc Company Information Table 97. Dermala Inc Business Overview Table 98. Dermala Inc Dermatomycoses Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Dermala Inc Dermatomycoses Drug Product Portfolio Table 100. Dermala Inc Recent Development Table 101. Daewoong Pharmaceutical Co Ltd Company Information Table 102. Daewoong Pharmaceutical Co Ltd Business Overview Table 103. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Portfolio Table 105. Daewoong Pharmaceutical Co Ltd Recent Development Table 106. Blueberry Therapeutics Ltd Company Information Table 107. Blueberry Therapeutics Ltd Business Overview Table 108. Blueberry Therapeutics Ltd Dermatomycoses Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Blueberry Therapeutics Ltd Dermatomycoses Drug Product Portfolio Table 110. Blueberry Therapeutics Ltd Recent Development Table 111. Biolab Farmaceutica Ltda Company Information Table 112. Biolab Farmaceutica Ltda Business Overview Table 113. Biolab Farmaceutica Ltda Dermatomycoses Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Biolab Farmaceutica Ltda Dermatomycoses Drug Product Portfolio Table 115. Biolab Farmaceutica Ltda Recent Development Table 116. Anacor Pharmaceuticals Inc Company Information Table 117. Anacor Pharmaceuticals Inc Business Overview Table 118. Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio Table 120. Anacor Pharmaceuticals Inc Recent Development Table 121. Key Raw Materials Table 122. Raw Materials Key Suppliers Table 123. Dermatomycoses Drug Distributors List Table 124. Dermatomycoses Drug Customers List Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Dermatomycoses Drug Product Image Figure 2. Global Dermatomycoses Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dermatomycoses Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Dermatomycoses Drug Sales (2021-2032) & (W Units) Figure 5. Global Dermatomycoses Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Dermatomycoses Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. BB-2603 Image Figure 10. Dapaconazole Image Figure 11. Clotrimazole Image Figure 12. Others Image Figure 13. Global Dermatomycoses Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Dermatomycoses Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Dermatomycoses Drug Sales Volume Share by Type (2021-2032) Figure 16. Global Dermatomycoses Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Dermatomycoses Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Dermatomycoses Drug Sales Value Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Clinic Image Figure 21. Others Image Figure 22. Global Dermatomycoses Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global Dermatomycoses Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global Dermatomycoses Drug Sales Volume Share by Application (2021-2032) Figure 25. Global Dermatomycoses Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Dermatomycoses Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global Dermatomycoses Drug Sales Value Share by Application (2021-2032) Figure 28. Global Dermatomycoses Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 29. Global Dermatomycoses Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global Dermatomycoses Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global Dermatomycoses Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America Dermatomycoses Drug Sales Value (2021-2032) & (US$ Million) Figure 33. North America Dermatomycoses Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe Dermatomycoses Drug Sales Value (2021-2032) & (US$ Million) Figure 35. Europe Dermatomycoses Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific Dermatomycoses Drug Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Dermatomycoses Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America Dermatomycoses Drug Sales Value (2021-2032) & (US$ Million) Figure 39. South America Dermatomycoses Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa Dermatomycoses Drug Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa Dermatomycoses Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt Dermatomycoses Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Dermatomycoses Drug Value Chain Figure 127. Manufacturing Cost Structure Figure 128. Dermatomycoses Drug Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • BB-2603
  • Dapaconazole
  • Clotrimazole
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Vyome Biosciences Pvt Ltd
  • Viamet Pharmaceuticals Inc
  • TGV-Laboratories
  • Sol-Gel Technologies Ltd
  • Novan Inc
  • Helix BioMedix Inc
  • Dermala Inc
  • Daewoong Pharmaceutical Co Ltd
  • Blueberry Therapeutics Ltd
  • Biolab Farmaceutica Ltda
  • Anacor Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Dermatomycoses Drug Sales Value (2021-2032)
  4. 1.2.2 Global Dermatomycoses Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Dermatomycoses Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Dermatomycoses Drug Market Dynamics
  1. 2.1 Dermatomycoses Drug Industry Trends
  2. 2.2 Dermatomycoses Drug Industry Drivers
  3. 2.3 Dermatomycoses Drug Industry Opportunities and Challenges
  4. 2.4 Dermatomycoses Drug Industry Restraints
3 Dermatomycoses Drug Market by Company
  1. 3.1 Global Dermatomycoses Drug Company Revenue Ranking in 2025
  2. 3.2 Global Dermatomycoses Drug Revenue by Company (2021-2026)
  3. 3.3 Global Dermatomycoses Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Dermatomycoses Drug Average Price by Company (2021-2026)
  5. 3.5 Global Dermatomycoses Drug Company Ranking (2024-2026)
  6. 3.6 Global Dermatomycoses Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Dermatomycoses Drug Company Product Type and Application
  8. 3.8 Global Dermatomycoses Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Dermatomycoses Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Dermatomycoses Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Dermatomycoses Drug Market by Type
  1. 4.1 Dermatomycoses Drug Type Introduction
  2. 4.1.1 BB-2603
  3. 4.1.2 Dapaconazole
  4. 4.1.3 Clotrimazole
  5. 4.1.4 Others
  6. 4.2 Global Dermatomycoses Drug Sales Volume by Type
  7. 4.2.1 Global Dermatomycoses Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Dermatomycoses Drug Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Dermatomycoses Drug Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Dermatomycoses Drug Sales Value by Type
  11. 4.3.1 Global Dermatomycoses Drug Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Dermatomycoses Drug Sales Value by Type (2021-2032)
  13. 4.3.3 Global Dermatomycoses Drug Sales Value Share by Type (2021-2032)
5 Dermatomycoses Drug Market by Application
  1. 5.1 Dermatomycoses Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Dermatomycoses Drug Sales Volume by Application
  6. 5.2.1 Global Dermatomycoses Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Dermatomycoses Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Dermatomycoses Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Dermatomycoses Drug Sales Value by Application
  10. 5.3.1 Global Dermatomycoses Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Dermatomycoses Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Dermatomycoses Drug Sales Value Share by Application (2021-2032)
6 Dermatomycoses Drug Regional Sales and Value Analysis
  1. 6.1 Global Dermatomycoses Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dermatomycoses Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Dermatomycoses Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Dermatomycoses Drug Sales by Region (2027-2032)
  5. 6.3 Global Dermatomycoses Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Dermatomycoses Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Dermatomycoses Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Dermatomycoses Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Dermatomycoses Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Dermatomycoses Drug Sales Value (2021-2032)
  12. 6.6.2 North America Dermatomycoses Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Dermatomycoses Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Dermatomycoses Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Dermatomycoses Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Dermatomycoses Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Dermatomycoses Drug Sales Value (2021-2032)
  21. 6.9.2 South America Dermatomycoses Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Dermatomycoses Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Dermatomycoses Drug Sales Value Share by Country, 2025 VS 2032
7 Dermatomycoses Drug Country-level Sales and Value Analysis
  1. 7.1 Global Dermatomycoses Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Dermatomycoses Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Dermatomycoses Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Dermatomycoses Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Dermatomycoses Drug Sales by Country (2027-2032)
  6. 7.4 Global Dermatomycoses Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Dermatomycoses Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Dermatomycoses Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Dermatomycoses Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Dermatomycoses Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Dermatomycoses Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Vyome Biosciences Pvt Ltd
  2. 8.1.1 Vyome Biosciences Pvt Ltd Company Information
  3. 8.1.2 Vyome Biosciences Pvt Ltd Business Overview
  4. 8.1.3 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Vyome Biosciences Pvt Ltd Dermatomycoses Drug Product Portfolio
  6. 8.1.5 Vyome Biosciences Pvt Ltd Recent Developments
  7. 8.2 Viamet Pharmaceuticals Inc
  8. 8.2.1 Viamet Pharmaceuticals Inc Company Information
  9. 8.2.2 Viamet Pharmaceuticals Inc Business Overview
  10. 8.2.3 Viamet Pharmaceuticals Inc Dermatomycoses Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Viamet Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio
  12. 8.2.5 Viamet Pharmaceuticals Inc Recent Developments
  13. 8.3 TGV-Laboratories
  14. 8.3.1 TGV-Laboratories Company Information
  15. 8.3.2 TGV-Laboratories Business Overview
  16. 8.3.3 TGV-Laboratories Dermatomycoses Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 TGV-Laboratories Dermatomycoses Drug Product Portfolio
  18. 8.3.5 TGV-Laboratories Recent Developments
  19. 8.4 Sol-Gel Technologies Ltd
  20. 8.4.1 Sol-Gel Technologies Ltd Company Information
  21. 8.4.2 Sol-Gel Technologies Ltd Business Overview
  22. 8.4.3 Sol-Gel Technologies Ltd Dermatomycoses Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sol-Gel Technologies Ltd Dermatomycoses Drug Product Portfolio
  24. 8.4.5 Sol-Gel Technologies Ltd Recent Developments
  25. 8.5 Novan Inc
  26. 8.5.1 Novan Inc Company Information
  27. 8.5.2 Novan Inc Business Overview
  28. 8.5.3 Novan Inc Dermatomycoses Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Novan Inc Dermatomycoses Drug Product Portfolio
  30. 8.5.5 Novan Inc Recent Developments
  31. 8.6 Helix BioMedix Inc
  32. 8.6.1 Helix BioMedix Inc Company Information
  33. 8.6.2 Helix BioMedix Inc Business Overview
  34. 8.6.3 Helix BioMedix Inc Dermatomycoses Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Helix BioMedix Inc Dermatomycoses Drug Product Portfolio
  36. 8.6.5 Helix BioMedix Inc Recent Developments
  37. 8.7 Dermala Inc
  38. 8.7.1 Dermala Inc Company Information
  39. 8.7.2 Dermala Inc Business Overview
  40. 8.7.3 Dermala Inc Dermatomycoses Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Dermala Inc Dermatomycoses Drug Product Portfolio
  42. 8.7.5 Dermala Inc Recent Developments
  43. 8.8 Daewoong Pharmaceutical Co Ltd
  44. 8.8.1 Daewoong Pharmaceutical Co Ltd Company Information
  45. 8.8.2 Daewoong Pharmaceutical Co Ltd Business Overview
  46. 8.8.3 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Daewoong Pharmaceutical Co Ltd Dermatomycoses Drug Product Portfolio
  48. 8.8.5 Daewoong Pharmaceutical Co Ltd Recent Developments
  49. 8.9 Blueberry Therapeutics Ltd
  50. 8.9.1 Blueberry Therapeutics Ltd Company Information
  51. 8.9.2 Blueberry Therapeutics Ltd Business Overview
  52. 8.9.3 Blueberry Therapeutics Ltd Dermatomycoses Drug Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Blueberry Therapeutics Ltd Dermatomycoses Drug Product Portfolio
  54. 8.9.5 Blueberry Therapeutics Ltd Recent Developments
  55. 8.10 Biolab Farmaceutica Ltda
  56. 8.10.1 Biolab Farmaceutica Ltda Company Information
  57. 8.10.2 Biolab Farmaceutica Ltda Business Overview
  58. 8.10.3 Biolab Farmaceutica Ltda Dermatomycoses Drug Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Biolab Farmaceutica Ltda Dermatomycoses Drug Product Portfolio
  60. 8.10.5 Biolab Farmaceutica Ltda Recent Developments
  61. 8.11 Anacor Pharmaceuticals Inc
  62. 8.11.1 Anacor Pharmaceuticals Inc Company Information
  63. 8.11.2 Anacor Pharmaceuticals Inc Business Overview
  64. 8.11.3 Anacor Pharmaceuticals Inc Dermatomycoses Drug Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Anacor Pharmaceuticals Inc Dermatomycoses Drug Product Portfolio
  66. 8.11.5 Anacor Pharmaceuticals Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dermatomycoses Drug Value Chain Analysis
  2. 9.1.1 Dermatomycoses Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dermatomycoses Drug Sales Mode & Process
  6. 9.2 Dermatomycoses Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dermatomycoses Drug Distributors
  9. 9.2.3 Dermatomycoses Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst